847579-32-2

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 57400-89-2 4-(3-aminopropyl)phenol 

Downstream Products

• 847579-33-3 tert-butyl N-(tert-butoxycarbonyl)-N-[3-(4-hydroxyphenyl)propyl]-β-alaninate 
• 847579-34-4 tert-butyl N-(tert-butoxycarbonyl)-N-{3-[4-(3-phenylpropoxy)phenyl]propyl}-β-alaninate 
• 847585-54-0 3-[(3-{4-[3-(4-methylphenyl)propoxy]phenyl}propyl)amino]propanoic acid hydrochloride 
• 847579-35-5 N-{3-[4-(3-phenylpropoxy)phenyl]propyl}-β-alanine hydrochloride 
• 475597-75-2 3-[3-(4-(5-phenylpentyloxy)phenyl)propylamino]propanoic acid hydrochloride 

Relevant academic research and scientific papers

Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety

Structure-activity relationship of sphingosine-1-phosphate receptor agonist was examined. In terms of reducing the flexibility of molecule, hit compound 1 was modified to improve S1P1 agonistic activity as well as selectivity over S1P3 agonistic activity. Novel S1P agonists with cinnamyl scaffold or 1,2,5,6-tetrahydropyridine scaffold were identified.

COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF

A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.